E-GEOD-2535 - Transcription profiling of human leukocytes from chronic myeloid leukemia patients exhibiting differing responses to imatinib
Submitted on 18 April 2005, released on 25 August 2007, last updated on 27 March 2012
This is a class prediction experiment, where the class is the response status to imatinib (also called Gleevec), a drug used to treat patients with chronic myelogenous leukemia (CML). There are two data sets, a training set (from Leipzig, 8 Responders and 5 Non-Responders) and a validation set (from Mannheim, 8 Responders and 7 Non-Responders). The objective is to identify differentially regulated genes between CML patients who respond and those who do not respond to imatinib and confirm the results in the validation data set. The samples from blood or bone marrow of CML patients were hybridized to Affymetrix HG-U95Av2 chip and RMA was used to generate the normalized signal values.
transcription profiling by array, clinical history, co-expression, organism part comparison
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Lucy C Crossman, Motomi Mori, Yi-Ching Hsieh, Thoralf Lange, Peter Paschka, Christina A Harrington, Knut Krohn, Dietger W Niederwieser, Rudiger Hehlmann, Andreas Hochhaus, Brian J Druker, Michael W N Deininger. Haematologica 90(4):459-64 (2005)